| Literature DB >> 24733356 |
Shi-Jun Li1, Hui-Ping Chen1, Ying-Hua Chen1, Li-hua Zhang1, Yuan-Mao Tu1, Zhi-hong Liu1.
Abstract
AIMS: To determine the spectrum of renal lesions in patients with kidney involvement in non-Hodgkin's lymphoma (NHL) by renal biopsy.Entities:
Mesh:
Year: 2014 PMID: 24733356 PMCID: PMC3986362 DOI: 10.1371/journal.pone.0095190
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical features of patients with NHL and renal involvement
| Patient | Sex | Age | Type of lymphoma | Biopsy site | Clinical symptoms of lymphoma | Renal symptoms | Treatment | Patient outcome | Renal Outcome (Scr µmol/l) |
|
| M | 16 | T/NK | Nasal mucosa | Anemia, fever, nasal discharge | RPGN | EPOCH | Died (1 yr) | NA |
|
| F | 38 | T/NK | Nasal mucosa | Fever, nasal discharge | NS | Steroids | Died (2 mo) | NA |
|
| F | 39 | TCL | Lymph node | Fever, lymphadenectasis | proteinuria | CHOP | Died (2 mo) | NA |
|
| M | 40 | TCL | Skin | Skin rash | NS | Steroids | NA | NA |
|
| M | 61 | CLL/SLL | Bone marrow | Anemia, weakness | AKI | Chlorambucil | Died (2 mo) | NA |
|
| F | 57 | CLL/SLL | Lymph node | Anemia, lymphadenectasis | RPGN | Chlorambucil | NA | NA |
|
| M | 64 | CLL/SLL | Lymph node | Lymphadenectasis | RPGN | FC | Died (3 mo) | NA |
|
| M | 55 | CLL/SLL | Lymph node | Lymphadenectasis | RPGN | FC | Alive (3 yr) | dialysis |
|
| M | 59 | CLL/SLL | Bone marrow | Leucocytosis | RPGN | Steroids | Alive (6 yr) | 126 |
|
| M | 61 | CLL/SLL | Bone marrow | Anemia, weakness | NS+AKI | FC | Alive (3 yr) | 137 |
|
| M | 68 | CLL/SLL | Bone marrow | Anemia, lymphadenectasis | NS+AKI | Steroids | Died (4 mo) | NA |
|
| M | 62 | CLL/SLL | Bone marrow | Anemia, leucopenia | AKI | CTX | Alive (1 yr) | 350 |
|
| M | 47 | DLBCL | Kidney | Fever, weakness | AKI | CHOP | Alive (1 yr) | 109 |
|
| M | 56 | DLBCL | Kidney | Anemia | AKI | CHOP | Died (2 yr) | NA |
|
| M | 62 | DLBCL | Lymph node | Anemia, lymphadenectasis | AKI | Steroids | Alive (8 yr) | 156 |
|
| M | 37 | DLBCL | Ileum | Fever, diarrhea | proteinuria | CHOP | Died (2 yr) | NA |
|
| M | 53 | LPL | Lymph node | Anemia, lymphadenectasis | proteinuria | Steroids | Alive (2 yr) | 89 |
|
| M | 68 | LPL | Bone marrow | Fever, Anemia, skin rash | proteinuria | CTX | Died (1 yr) | NA |
|
| M | 65 | MCL | Lymph node | Anemia, lymphadenectasis | NS+AKI | CHOP | Alive (1 yr) | 101 |
|
| M | 52 | MALT | Stoma mucosa | Anemia, stomachache | NS+AKI | R+Steroids | Alive (1 yr) | 249 |
CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma, DLBCL: diffuse larger B-cell lymphoma, T/NK:T/NK cell lymphoma, TCL: T-cell lymphoma, MALT: mucosa-associated lymphoid tissue lymphoma, MCL: mantle cell lymphoma, LPL: lymphoplasmacytic lymphoma, NS: nephritic syndrome,
AKI: acute kidney injury, RPGN: rapidly progressive glomerulonephritis, R: radiotherapy, NA: not available.
CHOP: cyclophosphamide, hydroxydaunomycin, oncovin, prednisone. CTX: cyclophosphamide.
EPOCH:Etoposide, prednisone, oncovin, cyclophosphamide, hydroxydaunomycin, FC: fludarabine, cyclophosphamide
Summary of clinical data in patients with NHL and renal involvement
| Patient | Hb (g/L) | WBC (*109/L) | Scr (µmol/l) | eGFR (ml/min) | albumin (g/L) | globulin (g/L) | Urine protein (g/d) | Urine RBC (104/ml) | Urine NAG (U/g·cr) | Urine RBP (mg/L) | Renal size (mm/mm) | Antibody or Cryo | SIFE |
|
| 70 | 6.6 | 187 | 44.8 | 33 | 31.3 | 2.72 | 2500 | 40.7 | 65.5 | 115/109 | N | N |
|
| 90 | 4.1 | 61 | 105 | 28.2 | 35.3 | 3.5 | 95 | 31.2 | 1.51 | 103/101 | ANA PR3-ANCA | N |
|
| 65 | 4.5 | 100 | 52.7 | 32.6 | 28.8 | 1.58 | N | 47.6 | 1.32 | 104/100 | N | N |
|
| 147 | 5.2 | 95 | 85.9 | 20.4 | 16.4 | 5.37 | 15 | 39.4 | 1.13 | 109/105 | N | N |
|
| 59 | 2.8 | 543 | 13 | 38.4 | 38.7 | 1.3 | 2000 | 40.2 | 7.78 | 106/102 | PR3-ANCA | N |
|
| 66 | 4.0 | 151 | 32.8 | 36.4 | 29.9 | 3.02 | 1850 | 94 | 1.88 | 99/98 | ANA | N |
|
| 91 | 5.1 | 338 | 15.6 | 36.5 | 26.3 | 1.41 | 1250 | 26.9 | 10.2 | 107/103 | A-GBM | N |
|
| 99 | 10.1 | 477 | 12.6 | 31.6 | 45.7 | 2.75 | 3000 | 35.5 | 10.2 | 127/122 | Cryo | N |
|
| 87 | 25.3 | 188 | 32.9 | 38.9 | 27.8 | 4.24 | 750 | 83.2 | 0.43 | 100/98 | N | N |
|
| 99 | 11.4 | 320 | 18.3 | 23.6 | 29.9 | 10.2 | 15 | 48.2 | 31.7 | 97/96 | N | IgM, k |
|
| 111 | 7.3 | 235 | 25.6 | 17.1 | 29.1 | 14.9 | 570 | 75.4 | 53.4 | 94/96 | N | IgM, k |
|
| 89 | 3.3 | 392 | 17.8 | 27.7 | 17.7 | 0.71 | N | 25.2 | 4.5 | 123/120 | Cryo | IgM, k |
|
| 135 | 8.8 | 158 | 46.3 | 44.2 | 29.7 | 0.39 | N | 20.2 | 10 | 167/146 | N | N |
|
| 98 | 5.6 | 166 | 37.2 | 40.6 | 27.4 | 0.84 | N | 32.4 | 3.44 | 114/110 | N | N |
|
| 113 | 4.2 | 168 | 34.2 | 38.3 | 15.5 | 1.24 | 47 | 21.1 | 0.13 | 103/101 | N | N |
|
| 107 | 10.6 | 77 | 103 | 36 | 18 | 0.68 | 50 | 25.7 | 0.1 | 106/101 | N | N |
|
| 109 | 4.5 | 74 | 103 | 34 | 40.3 | 0.41 | N | 26.2 | 0.93 | 129/120 | N | IgM, k |
|
| 78 | 9.4 | 50 | 95.8 | 27.2 | 18.8 | 0.7 | 230 | 82.3 | 0.84 | 111/110 | Cryo | N |
|
| 80 | 13.8 | 164 | 34.8 | 28.4 | 28.6 | 6.92 | 260 | 25 | 15.5 | 112/115 | N | N |
|
| 106 | 3.7 | 263 | 36.5 | 32.3 | 18.7 | 7.96 | 1100 | 119 | 11.9 | 112/106 | N | IgM, k |
Hb, hemoglobin; WBC, white blood count; BUN, blood urea nitrogen; SCr, serum creatinine; eGFR: estimated Glomerular Filtration Rate
NAG, N-acetyl-pD glucosaminidase enzyme, RBP: retinol-binding protein (RBP). ANA: antinuclear antibody, C-ANCA: antineutrophil cytoplasmic antibody, PR3-ANCA: anti-proteinase 3 ANCA, A-GBM: anti-glomerular basement membrane antibody, Cryo: cryoglobulinemia; SIFE: serum immunofixation electrophoresis, N negative
Renal biopsy findings
| Glomerular Disease | Infiltrating cells | Immunofluorescence | Immunoperoxidase | ||||||||||
| Glomerular | PTC | IgG | IgA | IgM | C3 | C1q | κ | λ | CD20(n/mm2) | CD68(n/mm2) | |||
|
| Crescent GN | >5 | Y | - | - | - | - | - | - | - | NA | 192 | |
|
| Crescent GN | 2–3 | Y | - | - | - | - | - | - | - | NA | NA | |
|
| NSPA | 2–3 | No | + | - | + | - | - | - | - | 96 | NA | |
|
| MCD | 2–3 | Y | - | - | - | - | - | - | - | Multifocal | 152 | |
|
| NSPA | >3 | Y | ++ | - | - | ++ | ++ | - | + | NA | 624 | |
|
| MPGN | >10 | Y | - | - | + | + | + | - | - | Diffuse | 548 | |
|
| Crescent GN | >5 | Y | ++ | - | - | - | - | - | + | Multifocal | Diffuse | |
|
| Crescent GN | >5 | Y | ++ | + | + | ++ | ++ | + | + | Multifocal | 592 | |
|
| MPGN | >10 | Y | ++ | + | ++ | ++ | + | ++ | + | Multifocal | 152 | |
|
| MCD | 3–5 | Y | - | - | - | - | - | - | - | 184 | 872 | |
|
| MCD | 3–5 | Y | - | - | - | - | - | - | - | 72 | 356 | |
|
| ICMDD | 3–5 | Y | - | - | ++ | - | - | ++ | - | Diffuse | 140 | |
|
| No glomerular | ND | Y | - | - | - | - | - | - | - | 192 | 1192 | |
|
| Lymphoma | ND | Y | - | + | + | - | - | - | - | 16 | 848 | |
|
| MPGN | >10 | Y | ++ | + | ++ | + | ++ | + | ++ | NA | NA | |
|
| MPGN | >10 | No | ++ | ++ | - | ++ | - | + | + | 144 | NA | |
|
| NSPA | 3–5 | Y | - | - | - | - | - | - | - | Multifocal | 312 | |
|
| MPGN | >5 | Y | - | ++ | - | ++ | - | + | - | Focal | 268 | |
|
| MPGN | >10 | No | ++ | - | - | ++ | ++ | - | + | 180 | 420 | |
|
| MPGN | >10 | No | ++ | ++ | - | ++ | - | ++ | + | NA | 312 | |
MPGN: Membranoproliferative glomerulonephritis. FSNGN: Focal segmental necrotizing glomerulonephritis. PTC:
ICMDD: Intracapillary monoclonal IgM deposits. Lymphoma: Intraglomerular lymphoma. MCD: Minimal-change disease NSPA:No specific pathologic abnormalities; NA: not available. Immunofluorescence: -, negative; +, mild; ++, intense. λ: λ light chain; κ: κ light chain.
Figure 1Representative renal histological change in patients with NHL.
A Light microscopy showed increased cellularity in glomeruli and the accentuation of the lobular architecture (patient 9 PAS×400). B Immunofluorescence showed granular staining in a lobular pattern for IgG (patient 9 IF×400). C Electron microscopy showed fine subendothelial electron-dense deposits (patient 9 EM). D Glomeruli with focal segmental necrosis and lymphoid cell infiltration around glomeruli (patient 8 Masson×400). E Glomeruli without pathological abnormalities visualized by LM with lymphocyte-like cell infiltration in the interstitial tissue (patient 5 PAS×200). F Mononuclear cell infiltration in the peritubular capillaries (patient 5 PAS×400).
Figure 2Diffuse infiltration into the renal parenchyma and intraglomerular lymphoma in DLBCL.
A. Accumulation of large atypical lymphoid cells was observed in renal specimens (patient 13 PAS×400). B. Immunohistochemical staining showing strong staining for CD20 in the lymphoid cells (patient 13 IH×400). C. Glomerular capillary lumina containing atypical large cells in the enlarged glomeruli (patient 14 PAS ×400). D Immunohistochemistry showing strong staining for CD20 in lymphoid cells localized within the glomerular capillary lumina (patient 14 IH×400).
Figure 3Intracapillary monoclonal deposition disease in an NHL patient (patient 12).
A PAS-positive intracapillary thrombi in glomerulus (PAS, ×200). B Immunofluorescence showed bright staining of the intraglomerular thrombi for IgM. C Immunofluorescence showed bright staining of the intraglomerular thrombi for κ LC.D Electron microscopy showed that the glomerular capillary lumen was filled with granular electron-dense material. No organized structure was observed.